[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibromyalgia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibromyalgia":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,121,0,25,[9,41,67,95,125,149,172,193,215,235,256,283,302,326,355,379,407,430,459,482,521,532,553,580,605],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053623","ultrasonic-neuromodulation-of-cingulate-cortex-for-fibromyalgia-100053623",false,"NCT07226648","Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia","Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia: A Blinded Randomized Sham-Controlled Trial","Inclusion Criteria:\n\n1. Willing and able to provide informed consent.\n2. Age ≥ 22 years.\n3. Meets 2016 American College of Rheumatology criteria for fibromyalgia:\n\n   1. Generalized pain, defined as pain in at least 4 of 5 regions, is present, AND\n   2. Widespread pain index (WPI) ≥ 7 and symptom severity scale score (SSS) ≥ 5, or WPI of 4-6 and SSS score ≥ 9, AND\n   3. Symptoms have been present at a similar level for at least 3 months, AND\n   4. A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.\n4. Failure of at least two evidence-based medications (i.e., pregabalin, duloxetine, milnacipran) for the treatment of fibromyalgia.\n5. Failure of one or more attempts at physical or Cognitive Behavioral Therapy (CBT) including:\n\n   1. Aerobic exercise like walking, cycling, and swimming,\n   2. Water therapy\u002Fhydrotherapy with warm water exercises,\n   3. Tai Chi involving slow, controlled movements,\n   4. Yoga,\n   5. Resistance training,\n   6. Bodyweight exercises,\n   7. Pilates,\n   8. Myofascial release therapy applying gentle pressure on trigger points,\n   9. Massage therapy,\n   10. Trigger point therapy targeting specific pain points,\n   11. Joint mobilization,\n   12. Postural retraining to correct body alignment,\n   13. Balance and coordination exercises,\n   14. Feldenkrais method for movement awareness,\n   15. Alexander technique to enhance posture and movement efficiency,\n   16. Transcutaneous Electrical Nerve Stimulation (TENS) for pain relief,\n   17. Heat therapy using hot packs, infrared, or paraffin wax,\n   18. Cold therapy with ice packs or cryotherapy,\n   19. Ultrasound therapy for deep tissue relaxation,\n   20. Biofeedback to control muscle tension and pain response,\n   21. Gentle static stretching for prolonged duration,\n   22. Active dynamic stretching for full range of motion,\n   23. Proprioceptive Neuromuscular Facilitation (PNF) stretching,\n   24. Hydrotherapy pool exercises,\n   25. Ai Chi (water-based Tai Chi),\n   26. Underwater treadmill therapy, aa) Graded motor imagery (GMI), bb) Mirror therapy to retrain brain-body connections, cc) Mindfulness-based stress reduction (MBSR) combining meditation and movement, dd) Balance exercises to improve stability, ee)Gaze stabilization techniques for dizziness and disorientation, ff) CBT.\n6. Pain score of ≥ 4 on Numerical Rating Scale (NRS-11) at Screening visit.\n7. Pain score of ≥ 4 on NRS-11 at Baseline visit averaged over 3 consecutive calendar days.\n8. Stated willingness and ability to comply with all study procedures.\n9. Has remained on the same psychiatric treatment regimen (e.g., medication, psychotherapy) for at least one (1) month prior to screening, and has stated willingness to remain on the same regimen for the duration of the study unless a change in treatment is recommended or agreed upon by the site investigator.\n10. For participants who could potentially become pregnant: negative urine pregnancy test at screening; agreement to use a highly effective method of contraception (≤ 1% pregnancy rate) including tubal ligation, vasectomized partner, IUD or IUS (intrauterine device or system), or long-acting contraceptives (LARC).\n\nExclusion Criteria:\n\n1. Any previous diagnosis of bipolar disorder or schizophrenia-spectrum disorder during the participant's lifetime, according to Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-5-TR) criteria.\n2. New or existing diagnosis of moderate or severe alcohol or other substance use disorder in the past 6 months, according to DSM-5-TR criteria.\n3. New or existing diagnosis of obsessive-compulsive disorder and\u002For posttraumatic stress disorder in the past 30 days, according to DSM-5-TR criteria, and which is unstable in the clinical judgment of the investigator.\n4. New or existing primary diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder in the past 3 months, according to DSM-5-TR criteria.\n5. Clinically significant neurodevelopmental, neurocognitive, or personality disorder, according to DSM-5-TR criteria.\n6. Moderate-High Risk of Suicide, according to the Columbia-Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (i.e., answers YES to Question 3 and NO to Question 6 (Moderate Risk), or YES to Question 4, 5, or 6 (High Risk)), or in the clinical judgement of the site investigator.\n7. Lifetime history of a serious suicide attempt in the medical opinion of the site investigator.\n8. Changes in treatment for pain in the past 2 months.\n9. Treatment with electroconvulsive therapy, transcranial magnetic stimulation, ketamine, or esketamine in the past 30 days.\n10. Currently diagnosed progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapid progressive arachnoiditis, brain or spinal cord tumor, or severe\u002Fcritical spinal stenosis (stenosis).\n11. Cancer-related pain.\n12. Diagnosis of malignancy other than basal cell carcinoma, or carcinoma in situ of the cervix within the past five years, to include life expectancy less than one year due to advanced malignancy.\n13. Autoimmune-related pain.\n14. Inadequately managed general medical condition, in the opinion of the site investigator.\n15. Lifetime history of cerebral small vessel disease.\n16. Lifetime history of intracranial hemorrhage.\n17. Pregnant or breast feeding.\n18. Implanted medical device in the head or neck.\n19. MRI contraindication or intolerance.\n20. Previously enrolled in a DIADEM clinical trial. Note: a patient who screen fails is able to be rescreened at most one time.\n21. Has a history of any medical or psychiatric disorder, disease, condition, injury, symptoms, or circumstance that, in the opinion of the site investigator, may (1) reduce the participant's ability to fulfill the study requirements as per protocol; (2) adversely impact the integrity of the data or the validity of the study results; or (3) pose an increased risk to the participant during study participation.\n22. Participants with braids, dreadlocks, or other hairstyles that prevent access to the side of the head and who are unwilling to temporarily adjust their hairstyle to allow such access.","ALL","22 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate a new noninvasive brain stimulation intervention for fibromyalgia and to determine its effectiveness in reducing pain. Participants will receive four treatments over the course of one month and will complete surveys at multiple time points throughout the 16-week study.",[27],"Fibromyalgia","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-12-11",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"SPIRE Therapeutics Inc.","INDUSTRY",8,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100645400","impact-of-major-ozone-autohemotherapy-on-sarcopenia-parameters-in-fibromyalgia-100645400","NCT07680621","Impact of Major Ozone Autohemotherapy on Sarcopenia Parameters in Fibromyalgia","Effects of Major Ozone Autohemotherapy on Sarcopenia Parameters and Clinical Features in Fibromyalgia","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria:\n* Symptoms present at a similar level for at least 3 months\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity Scale (SSS) ≥ 5\n* WPI 4-6 and SSS ≥ 9\n* Not currently receiving medical treatment for fibromyalgia (except NSAIDs)\n\nExclusion Criteria:\n\n* Current or previous pharmacological treatment specifically for fibromyalgia\n* Pregnancy or breastfeeding\n* History of active or previous malignancy\n* History of systemic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, dermatomyositis, familial Mediterranean fever)\n* Endocrine disorders (e.g., hypothyroidism, Cushing's syndrome, adrenal insufficiency)\n* Anemia\n* Chronic renal failure\n* Chronic liver failure\n* Chronic obstructive pulmonary disease (COPD)\n* Known severe cardiovascular disease\n* Body mass index (BMI) \\> 30 kg\u002Fm²\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency","18 Years","65 Years",{"count":51,"type":21},60,[24],"Fibromyalgia syndrome (FMS) is a chronic and heterogeneous disorder characterized primarily by widespread pain, accompanied by sleep disturbances, fatigue, depressive symptoms, and cognitive dysfunction. Although multiple therapeutic options are available, no curative treatment currently exists. Previous studies have demonstrated increased oxidative stress, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and a predisposition to sarcopenia in patients with FMS.\n\nOzone therapy has increasingly been used in chronic diseases due to its regulatory effects on oxidative stress. Although ozone is inherently an oxidative molecule, when administered at therapeutic doses it may induce antioxidant responses at the cellular level and exert anti-inflammatory effects by modulating inflammatory mediators. However, limited studies have evaluated the efficacy and underlying mechanisms of major ozone autohemotherapy (MOA) in FMS.\n\nThis controlled, prospective, single-blind study aims to investigate the effects of major ozone autohemotherapy on clinical parameters of FMS, as well as its impact on HPA axis function and sarcopenia-related parameters. A total of 60 patients with FMS will be enrolled and randomized into two groups: (1) exercise therapy alone and (2) exercise therapy plus major ozone autohemotherapy. MOA will be administered twice weekly for a total of 10 sessions at a dose of 20-40 μg\u002FmL.\n\nParticipants will be evaluated at baseline, at week 6, and at 3 months. Outcome measures will include Visual Analog Scale (VAS), Fibromyalgia Impact Questionnaire (FIQ), Fatigue Severity Scale (FSS), Pittsburgh Sleep Quality Index (PSQI), Short Form-12 (SF-12), and Hospital Anxiety and Depression Scale (HADS). Morning fasting serum cortisol levels will be measured to assess HPA axis function. Sarcopenia assessment will include handgrip strength measured by Jamar dynamometer, and ultrasonographic evaluation of muscle mass, muscle thickness, pennation angle, fascicle length, echogenicity, and cross-sectional area. Physical performance will be assessed using the Short Physical Performance Battery (SPPB).\n\nUnlike previous studies, this trial includes a 3-month follow-up evaluation after completion of ozone therapy to assess longer-term effects. By incorporating objective sarcopenia and endocrine assessments alongside validated clinical scales, the study aims to provide comprehensive evidence regarding the role of major ozone autohemotherapy in FMS management. This will be the first study to specifically evaluate the effects of major ozone autohemotherapy on sarcopenia parameters in patients with FMS.",[27],"NOT_YET_RECRUITING","2026-07-01",{"date":58,"type":32},"2026-07-02",{"date":60,"type":21},"2026-08",{"date":62,"type":21},"2027-03",{"name":64,"class":65},"Sakarya University","OTHER",1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100644668","ai-and-computer-vision-assisted-telerehabilitation-in-fibromyalgia-the-fibroia-20-trial-100644668","NCT07674485","AI and Computer Vision-Assisted Telerehabilitation in Fibromyalgia: The FibroIA 2.0 Trial","Effectiveness of Artificial Intelligence- and Computer Vision-Assisted Telerehabilitation, With and Without Resistance Training, on Disease Impact and Physical Function in People With Fibromyalgia: A Randomized Controlled Trial (FibroIA 2.0)","fibroIA 2","Inclusion Criteria:\n\n* Adults aged 18 years or older, of any sex\u002Fgender, with a documented medical diagnosis of fibromyalgia established in primary or secondary healthcare settings according to the American College of Rheumatology (ACR) criteria (Häuser \\& Fitzcharles, 2018).\n* Individuals able to understand and complete the self-report questionnaires used in the study.\n* Individuals with access to a compatible electronic device (smartphone, tablet, or computer) and an internet connection required for participation in the telerehabilitation intervention.\n* Individuals with basic digital literacy skills, defined as the ability to use electronic devices and interact with commonly used applications.\n* Individuals who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Current participation in another structured therapeutic exercise program, whether supervised or unsupervised.\n* Moderate to severe functional dependence in activities of daily living, defined as a score \\\u003C60 on the Barthel Index.\n* Absolute contraindications to therapeutic exercise, including hypertensive crisis (≥170\u002F110 mmHg), dyspnea at rest, resting tachycardia, or severe glycemic abnormalities (blood glucose \\>250 mg\u002FdL or \\\u003C90 mg\u002FdL in individuals receiving insulin therapy).\n* Severe uncontrolled pain, defined as a score ≥8 on the Numeric Pain Rating Scale (NPRS) at rest.\n* Medical or neurological conditions that significantly limit the safe performance of physical exercise, as determined by clinical assessment.\n* Recent changes in fibromyalgia-specific pharmacological treatment within the previous 4 weeks, to ensure clinical stability throughout the intervention period.",{"count":76,"type":21},66,[24],"Fibromyalgia (FM) is a primary chronic pain condition with an estimated prevalence of 3.3% in Chile. It is characterized by widespread musculoskeletal pain, fatigue, and impaired physical function. Although exercise therapy is considered the first-line intervention, barriers to access and poor adherence limit its effectiveness within the public healthcare system. This study evaluates the effectiveness of an Artificial Intelligence (AI)- and Computer Vision (CV)-assisted telerehabilitation platform called Rehbody. The aim is to determine whether real-time technology-driven feedback can overcome the limitations of traditional face-to-face rehabilitation models by improving disease impact and functional capacity in Chilean patients with fibromyalgia.",[27,80,81],"Fibromyalgia (FM)","Fibromyalgia Syndrome",[83,84,85,86],"fibromyalgia","exercise","telehealth","artificial intelligence","2026-06-28",{"date":56,"type":32},{"date":90,"type":21},"2027-01-04",{"date":92,"type":21},"2027-06-21",{"name":94,"class":65},"Instituto Neurociencia Del Dolor",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100645231","emotional-allodynia-questionnaire-aeq-in-fibromyalgia-pearl-100645231","NCT07677631","Emotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL)","Pain, Emotional Allodynia, and Relational Load (PEARL): A Multicenter Validation Study of the Emotional Allodynia Questionnaire in Fibromyalgia","PEARL","CASES (fibromyalgia)\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Clinical diagnosis of fibromyalgia confirmed according to the 2016 revision of the ACR criteria\n* Chronic non-cancer pain for at least 3 months\n* Ability to understand and independently complete self-report questionnaires in Italian\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Active oncological disease or cancer-related pain\n* Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder (assessed by clinical history)\n* Severe cognitive impairment precluding questionnaire completion\n* Inability to understand or complete questionnaires in Italian\n\nCONTROLS (non-fibromyalgia chronic pain)\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Chronic non-cancer pain for at least 3 months with a defined nociceptive or neuropathic generator (e.g., radiologically or surgically documented degenerative, structural, or post-surgical musculoskeletal pain, or neuropathic pain with an identifiable neurological lesion or disease)\n* Not meeting the 2016 ACR criteria for fibromyalgia\n* Ability to understand and independently complete self-report questionnaires in Italian\n* Willingness to provide written informed consent\n\nExclusion Criteria (parallel to cases):\n\n* Diagnosis of fibromyalgia or another recognized nociplastic primary pain condition (e.g., primary chronic widespread pain)\n* Active oncological disease or cancer-related pain\n* Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder\n* Severe cognitive impairment precluding questionnaire completion\n* Inability to understand or complete questionnaires in Italian\n\nNote: ongoing pharmacological treatment for pain or mental health is not an exclusion criterion in either group; Major Depressive Disorder and Panic Disorder are recorded at baseline and used in covariate-adjusted and stratified analyses.",{"count":104,"type":21},423,"OBSERVATIONAL","The Emotional Allodynia Questionnaire (AEQ) is an 11-item self-report instrument that measures disproportionate emotional reactivity to low-intensity interpersonal cues(perceived unresponsiveness, exclusion, loss of reciprocity), a pattern termed emotional allodynia. It was preliminarily validated in a single-center fibromyalgia sample. PEARL (validation phase) is a multicenter, prospective, observational psychometric validation study that (1) replicates the internal structure and convergent validity of the AEQ in an independent fibromyalgia sample, (2) tests its known-groups (discriminative) accuracy in separating fibromyalgia from non-fibromyalgia chronic pain of defined nociceptive or neuropathic origin, expressed as the area under the ROC curve (AUC), and (3) assesses test-retest reliability. There is no intervention.",[27,108,109],"Chronic Pain","Nociplastic Pain",[111,27,112,113,114,115],"Emotional Allodynia Questionnaire","Nociplastic pain","Psychometric validation","Central sensitization","Emotion regulation","2026-06-24",{"date":56,"type":32},{"date":119,"type":32},"2025-09-10",{"date":121,"type":21},"2027-08",{"name":123,"class":65},"University of Bari",5,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":49,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":66},"100521227","early-phase-1-mdma-assisted-therapy-for-fibromyalgia-100521227","NCT06066853","MDMA-assisted Therapy for Fibromyalgia","Hyperscan Neuroimaging to Reveal the Brain Mechanisms Supporting Analgesia Following MDMA-assisted Therapy for Fibromyalgia","Inclusion Criteria:\n\n* Are at least 21 years to 65 years of age inclusive, at the time of signing the informed consent.\n* Have a clinical diagnosis of fibromyalgia and meet the Wolfe et al 2011 research criteria for fibromyalgia for at least one year.\n* Typical fibromyalgia pain intensity of 4\u002F10 or greater.\n* Fluent in speaking and reading English.\n* Able to swallow pills.\n* Agree to have some study visits audiovisually recorded, including Experimental Sessions\u002F neuroimaging sessions.\n* Able to provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of the participant becoming unwell or unreachable.\n* Able to identify appropriate support person(s) to stay with the participant on the evenings of the Experimental Sessions\n* Have a body weight of at least 45 kilograms (kg). Participants with a body weight of 45 to 48 kg must also have a body mass index (BMI) within the range of 18 to 30 kg\u002Fm2\n* Participants assigned female sex at birth must not be pregnant or become pregnant throughout participation in the study\n* Capable of giving signed informed consent\n* Are on stable doses of allowable medication for 30 days prior to entering the study and agree not to change medications or dosages during the trial, except for medications falling under the tapering scheduling\n\nExclusion Criteria:\n\n* Presence of any medical or psychiatric illness that is judged to interfere with the study (ex. Fibromyalgia, PTSD, bipolar, schizophrenia) determined by a self-report measure.\n* Presence of any contraindications to fMRI scanning or EEG scanning. (ex. Cardiac pacemaker, metal implants, fear of enclosed spaces, pregnancy).\n* Unwillingness to receive brief experimental pain\n* Lower extremity pain or vascular issues that may interfere with the study procedures\n* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.\n* Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, heart failure, severe coronary artery disease, or aneurysm.\n* Have a diagnosis of uncontrolled hypertension, defined as repeated blood pressure readings of ≥140 mmHg systolic or ≥90 mmHg diastolic.\n* Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n* Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.\n* Have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening.\n* Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n* Have engaged in a new form of psychiatric or mental health care within 12 weeks of enrollment, including Electroconvulsive Therapy (ECT), and ketamine-assisted therapy.\n* Have a current moderate or severe alcohol or cannabis use disorder within the 12 months prior to enrollment.\n* Have an active illicit drug (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment.\n* Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion.\n* Unable or unwilling to safely taper-off prohibited psychiatric and non-psychiatric medication with exceptions determined by study staff or require use of prohibited medications during experimental sessions.\n* Require use of concomitant medications that could prolong the QT interval during Experimental Sessions.\n* Have used Ecstasy (unregulated material represented as containing MDMA) more than 10 times within the last 10 years, or at least once within 6 months of the first Experimental Session.\n* Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research, unless approved by the study clinician.\n* Have current Personality and\u002For Psychotic Disorders.\n* Have a current eating disorder with compensatory behaviors.\n* Have current major depressive disorder with psychotic features.\n* Have a history of, or a current primary psychotic disorder, bipolar affective disorder type 1.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the sponsor-investigator or study clinician, contraindicates participation in the study.\n* Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of fibromyalgia or any psychiatric disorders.\n* Lack social support or lack a stable living situation.\n* Previous participation in a MAPS-sponsored MDMA clinical trial.\n* Employees (and their immediate family members) of MAPS, MAPS Public Benefit Corporation, or MAPS Europe B.V; or individuals in a personal relationship with the site investigator.\n* Presence of any medical or psychiatric illness that is judged to interfere with trial\n* Presence of any contraindications to fMRI scanning or EEG scanning (ex. Cardiac pacemaker, metal implants, fear of closed spaces)\n* Lower extremity pain or vascular issues that may interfere with study procedures\n* Comorbid chronic pain condition that is rated by the subject as more painful than fibromyalgia\n* Have any severe anxiety disorders or significant anxiety symptoms interfering with fMRI scanning (e.g. panic)\n* Is a current patient of the matched dyad clinician enrolled in the study\n* Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist.\n* Have any current problem which, in the opinion of the sponsor-investigator or study clinician, might interfere with study participation or prevent satisfactory completion of study protocol.","21 Years",{"count":134,"type":21},20,[136],"EARLY_PHASE1","Fibromyalgia is a debilitating chronic pain disorder. Based on prior research with MDMA, it can be hypothesized MDMA-assisted therapy in fibromyalgia patients may increase the range of positive emotions, interpersonal trust, and heighten the state of empathic rapport that can lead to an enhanced patient-clinician interaction and to initiate reattribution processes targeting dysfunctional thoughts towards pain. Therapeutic alliance, i.e. a positive patient-clinician relationship, is already acknowledged as an essential component for MDMA-assisted therapy. Despite its importance, the patient-clinician interaction and the neuroscience supporting patient\u002Fclinician therapeutic alliance has received almost no attention in MDMA research. The investigators will examine the potential therapeutic benefit of MDMA-assisted therapy for fibromyalgia. Additionally, this study will also target secondary objectives including the investigation of the clinical and physiological response (i.e. brain-to-brain concordance) supporting enhanced patient-clinician therapeutic alliance in fibromyalgia patients. The study includes two Experimental Sessions of therapy with MDMA combined with neuroimaging, along integrative therapy, baseline neuroimaging, and a 3 month follow up.",[27],[140,27,141,142],"N-Methyl-3,4-methylenedioxyamphetamine","MDMA","Pain",{"date":144,"type":32},"2026-06-29",{"date":56,"type":21},{"date":36,"type":21},{"name":148,"class":65},"Spaulding Rehabilitation Hospital",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":66},"100605079","the-efficacy-and-safety-of-pregabalin-and-mirogabalin-in-patients-with-fibromyalgia-100605079","NCT07157852","The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia","Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Mirogabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Newly diagnosed with FM according to the 2016 Revisions to the 2010\u002F2011 FM diagnostic criteria;\\[1\\]\n* Aged over 18 years old;\n* Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM;\n* Baseline numeric rating scale (NRS) score of 4 or higher;\n* Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range;\n* Estimated glomerular filtration rate (eGFR) of at least 30 mL\u002Fmin\u002F1.73 m²;\n* Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements;\n\nExclusion Criteria:\n\n* Previous allergic reactions to pregabalin, mirogabalin, or any of their excipients;\n* Prior diagnosis of epilepsy or depression requiring antidepressant therapy;\n* Women who are pregnant or breastfeeding;\n* Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment;\n* Suffering from acute or chronic pain disorders other than FM.",{"count":157,"type":21},674,[24],"Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Mirogabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or mirogabalin in treating FM, with the aim of providing a better treatment option for FM patients.",[27,161,162,142],"Pregabalin","Mirogabalin","2026-06-23",{"date":165,"type":32},"2026-06-25",{"date":167,"type":32},"2025-09-05",{"date":169,"type":21},"2027-08-31",{"name":171,"class":65},"Beijing Tiantan Hospital",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":178,"minAge":48,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":66},"100560600","the-effects-of-core-shamanism-in-fibromyalgia-100560600","NCT06579261","The Effects of Core Shamanism in Fibromyalgia","Inclusion Criteria for Fibromyalgia participants:\n\n* Female\n* Over 18 and under 75 years of age.\n* Fibromyalgia patients and satisfies the 2016 Fibromyalgia Diagnostic Criteria for the classification of FM.\n* Mean recalled pain over the last seven days (7-day recall) greater than or equal to 4 on a 10 cm Visual Analog Scale (VAS) for pain; 7-day recall.\n* Willing to limit the introduction of any new medications or treatment modalities for control of FM symptoms during the study.\n* Able to travel to the study site to receive shamanic treatments up to twice weekly.\n* Understanding and willing to complete all study procedures.\n* Capable of giving written informed consent.\n* Proficient ability to speak, read, and write in english.\n\nExclusion Criteria:\n\n* Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain.\n* History of head injury with substantial loss of consciousness\n* Peripheral neuropathy of known cause that interferes with activities of daily living.\n* Routine daily use of opioid analgesics, marijuana, or history of substance abuse.\n* Stimulant medications, such as those used to treat Attention Deficit Disorder (ADD)\u002FAttention-deficit\u002Fhyperactivity disorder (ADHD). (e.g., amphetamine\u002F dextroamphetamine \\[Adderall®\\], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil), are excluded.\n* Concurrent participation in other therapeutic trials.\n* Use of as needed (PRN) over the counter (OTC) pain medications (Nonsteroidal anti-inflammatory drugs (NSAIDs), etc.) on day of electroencephalogram (EEG) testing.\n* Use of PRN opioid analgesics 48 hours prior to electroencephalogram (EEG) testing.\n* Pregnant or nursing. A pregnancy test will be given prior to electroencephalogram (EEG) sessions.\n* Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years).\n* Contraindications to EEG methods. These may include but are not limited to: surgical clips, surgical staples, metal implants, and certain metallic dental material.\n* Any impairment, activity or situation that is in the judgment of the Study Coordinator or Principal Investigator that would prevent satisfactory completion of the study protocol. This includes unreliable, or inconsistent pain scores as deemed by the principal investigator.\n* Sufficient knowledge of Shamanism techniques that may bias participant outcomes.\n* Presence of factors that may preclude the safe use of the Shamanism intervention.\n* History vascular surgery in lower limbs or current lower limb vascular dysfunction.\n* Presence of uncontrolled cardiovascular disease.\n* Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's fibromyalgia; current involvement in out-of-court settlements for claims pertinent to the subject's fibromyalgia; or currently receiving monetary compensation as a result of any of the above.\n* Inability or unwillingness of an individual to give written informed consent.","FEMALE","75 Years",{"count":7,"type":21},[24],"This study aims to determine the feasibility of a shamanism intervention for patients with fibromyalgia, acquire efficacy data to determine if Shamanism reduces clinical pain and other common symptoms associated with fibromyalgia, and determine if the Shamanism intervention changes heart rate electrocardiogram (ECG), breathing rate, and brain wave electroencephalogram (EEG) outcomes in fibromyalgia patients and shamanic practitioners.\n\nThe investigators hypothesize that 80% of individuals will complete at least 80% of study visits, clinical pain severity and\u002For interference will be significantly reduced following the Shamanic intervention, and lung, heart, and\u002For brain activity will be altered with the Shamanic intervention and also become more synchronized between Shamanic Practitioners (SPs) and patients during the course of treatment.",[27],[185],"fibromyalgia chronic pain","2026-06-18",{"date":163,"type":32},{"date":189,"type":32},"2024-08-01",{"date":36,"type":21},{"name":192,"class":65},"University of California, Irvine",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":66},"100641869","advancing-online-psychology-tools-for-chronic-pain-100641869","NCT07659873","Advancing Online Psychology Tools for Chronic Pain","Advancing Online Psychology Tools for Chronic Pain (ADOPT-CP): Feasibility of a Scalable Digital Psychology Intervention and AI-Powered Support for Patients on the Waitlist for Pain Services","ADOPT-CP","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent;\n2. Must sign and date the informed consent form;\n3. Must state willingness to comply with all study procedures;\n4. Must be at least 18 years of age;\n5. Must be referred to TAPMI;\n6. Must have either fibromyalgia or chronic pelvic pain\n7. Must be on the waitlist at TAPMI;\n8. Must have access to a device that can connect to the Internet with access to email.\n\nExclusion Criteria:\n\n1. Currently engaged in psychotherapy or engaged in psychotherapy within the last month at the time of enrolment;\n2. Unable to read, understand, or communicate in English sufficiently to provide informed consent and complete the study procedures and questionnaires;\n3. Has active serious mental illness or psychiatric instability that, in the opinion of the research team, may impair the ability to safely participate in the study or to provide informed consent (e.g., active psychosis, active mania);\n4. Has a visual, auditory, or other functional impairment that would prevent independent access to and use of the digital intervention and study procedures on an internet-enabled device.",{"count":51,"type":21},[24],"Chronic pain affects more than 20% of Canadians and is associated with significant impacts on physical function, mental health, and quality of life. Despite efforts to improve access to multidisciplinary pain care through centralized referral systems, many patients continue to experience prolonged wait times before receiving treatment.\n\nThis study evaluates a self-guided digital psychological intervention designed to support chronic pain self-management during the waiting period for specialized pain care. The intervention was developed through a collaboration between the Transitional Pain Service and ManagingLife and aims to improve access to evidence-based psychological support, enhance self-management skills, and reduce pain-related distress among individuals living with chronic pain.",[27,205],"Chronic Pelvic Pain Syndrome","2026-06-15",{"date":208,"type":32},"2026-06-22",{"date":210,"type":21},"2026-10",{"date":212,"type":21},"2028-03",{"name":214,"class":65},"Women's College Hospital",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":178,"minAge":48,"maxAge":49,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":66},"100625670","physiotherapy-methods-for-fibromyalgia-100625670","NCT07425652","Physiotherapy Methods for Fibromyalgia","Comparison of the Effects of Different Physiotherapy Methods in Women With Fibromyalgia","Inclusion Criteria:\n\n* Having been diagnosed with fibromyalgia\n* Being female between the ages of 18-65\n* Volunteering to participate in the study\n\nExclusion Criteria:\n\n* Diagnosed neurological and infectious diseases\n* Uncontrolled endocrine and\u002For autoimmune diseases\n* Serious psychiatric disorders (bipolar disorder, schizophrenia, psychosis, etc.)\n* Pregnancy or breastfeeding\n* Malignancy\n* History of known arrhythmia or any implanted electronic device\n* Presence of sensory loss\n* Acute inflammation, open wounds, erythema in massage areas\n* History of any surgery within the last 6 months\n* Having received physical therapy for FM within the last 6 months and\u002For being included in a new treatment program during the study period",{"count":76,"type":21},[24],"The aim of our study was to examine and compare the effects of different physiotherapy methods, namely connective tissue massage, transcutaneous auricular vagus nerve stimulation and both, on pain, health status, sleep quality, fatigue, psychosocial status, autonomic symptoms and quality of life in women with fibromyalgia.",[27],"2026-06-13",{"date":228,"type":32},"2026-06-16",{"date":230,"type":32},"2026-03-01",{"date":232,"type":21},"2028-01",{"name":234,"class":65},"Ankara Yildirim Beyazıt University",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":66},"100559974","analgesic-response-to-opioids-in-patients-with-fibromyalgia-after-conventional-acupuncture-versus-sham-acupuncture-100559974","NCT06571110","Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture","Inclusion Criteria:\n\n* Are 18 - 80 years old\n* have been diagnosed with Fibromyalgia for more than 6 months\n* Are already using chronic, continuous opioid therapy, including but not limited to the use of Hydrocodone (Norco), Oxycodone (Percocet), morphine, methadone or Tylenol #3 daily\n* Have moderate to excruciating pain at baseline, determined by a 5 or greater score on the Visual Analogue Scale (VAS)\n\nExclusion Criteria:\n\n* Are younger than 18 or older than 80 years old\n* Have been diagnosed with a Substance Use Disorder (SUD)\n* Pregnant\n* Have an active litigation or worker's compensation case\n* Have an active mental health diagnosis, such as bipolar disorder, psychosis, or suicidal ideation\n* Are prescribed and actively using low dose Naltrexone . Have tried acupuncture in the last 6 months","80 Years",{"count":243,"type":21},45,[24],"This study aims to see whether acupuncture can help fibromyalgia patients by giving them acupuncture treatment and seeing whether acupuncture helps enhance the effects of an opioid.",[27],[248],"Acupunture","2026-06-11",{"date":206,"type":32},{"date":252,"type":32},"2025-03-15",{"date":254,"type":21},"2027-12-01",{"name":192,"class":65},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":241,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":66},"100642658","analgesic-efficacy-of-multisite-rtms-in-fibromyalgia-patients-100642658","NCT07642882","Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients","Analgesic Efficacy of Multisite rTMS in Depressed and Nondepressed Patients With Fibromyalgia and Prediction of the Response: a Double-Blind Randomized Sham-Controlled Study.","MultiStimFM","Inclusion Criteria:\n\n* Chronic pain lasting at least 6 months, with or without associated depressive symptoms;\n* Fibromyalgia (2016 revised ACR criteria and a FIRST questionnaire score of at least 5 out of 6);\n* Average pain intensity ≥ 4\u002F10 on a 0-10 numeric rating scale;\n* Pain present daily or almost daily (≥ 4 days per week);\n* Patients aged over 18 and under 80 years;\n* Patients who have provided written informed consent;\n* Patients whose analgesic treatment has been stable for at least 1 month prior to inclusion and will not need to be modified during the study;\n* Patients who can be followed for the duration of the study (10 weeks);\n* Patients covered by a health insurance plan or otherwise eligible.\n\nExclusion Criteria:\n\n* Ongoing litigation;\n* Contraindication to rTMS:\n* Implanted electronic devices and\u002For conductive objects near the coil: Patients with an active implanted device that is activated or controlled by physiological signals (e.g., pacemakers, implantable cardiac defibrillators \\[ICD\\], vagus nerve stimulators \\[VNS\\], wearable cardioverter defibrillators \\[WCD\\], ocular implants, deep brain stimulation systems, drug infusion pumps or ports, intracardiac leads), even if the device has been removed.\n* Non-removable metallic objects near the coil:\\*\\* Patients with a conductive, ferromagnetic, or magnetically sensitive metal implant in the head or within 30 cm of the coil (e.g., cochlear implants, implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, or bullet fragments);\n* Current abuse of drugs or psychoactive substances, including alcohol (according to DSM-5 criteria);\n* Pregnancy or breastfeeding;\n* Epilepsy or a history of epilepsy;\n* Unstable or progressive medical conditions (e.g., cancer);\n* Psychosis according to DSM-5 criteria;\n* Presence of another pain condition more severe than the one qualifying for inclusion;\n* Failure to correctly complete pain self-assessment diaries between inclusion and randomization (fewer than 4 pain scores recorded over 7 days);\n* Inability to understand the informed consent form, or subjects under legal guardianship or curatorship;\n* Participation in another research protocol within 30 days prior to inclusion.",{"count":265,"type":21},36,[24],"Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex is a recognized analgesic technique for the treatment of fibromyalgia pain, which represents a largely unmet medical need. However, the effectiveness of motor cortex rTMS is inconsistent, being observed in only about 40% of patients and not always long-lasting. It has been previously shown that predictive factors for a lack of response to motor cortex rTMS include the presence of depressive symptoms, and that prefrontal cortex rTMS is not effective for pain, even though this treatment has proven efficacy in major depressive disorder.\n\nThe hypothesis is that targeting both the motor and prefrontal cortices with rTMS will yield a particularly beneficial effect in fibromyalgia patients presenting with comorbid depressive symptoms.\n\nGiven the absence of established biomarkers for predicting rTMS response, an additional aim will be to develop reliable indicators of rTMS efficacy, based on clinical phenotype and measurements of oscillatory patterns assessed by electroencephalogram (EEG) recordings.",[27,269,108],"Depression - Major Depressive Disorder",[27,108,271,272,273,274],"rTMS","Depression","Neuromodulation","EEG","2026-06-08",{"date":249,"type":32},{"date":278,"type":21},"2026-09",{"date":280,"type":21},"2028-11",{"name":282,"class":65},"Hospital Ambroise Paré Paris",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":178,"minAge":48,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100643176","manual-diaphragmatic-release-on-exercise-capacity-and-quality-of-life-in-women-with-fibromyalgia-100643176","NCT07641166","Manual Diaphragmatic Release on Exercise Capacity and Quality of Life in Women With Fibromyalgia","Effect of Manual Diaphragmatic Release on Exercise Capacity and Quality of Life in Women With Fibromyalgia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Confirmed clinical diagnosis of fibromyalgia fulfilling the American College of Rheumatology diagnostic criteria.\n* Sedentary or low physical activity status (not participating in structured exercise programs within the past 3 months).\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities (e.g., major depressive disorder with active suicidal ideation) or cognitive impairments.\n* Presence of comorbid rheumatologic or autoimmune conditions that overlap with muscle\u002Fjoint symptoms (e.g., severe rheumatoid arthritis, systemic lupus erythematosus).\n* Primary chronic respiratory\u002Fchest diseases (e.g., severe COPD or active asthma).\n* Cardiovascular disorders or uncontrolled hypertension.\n* Pregnancy.","55 Years",{"count":51,"type":21},[24],"Evaluate the effect of manual diaphragmatic release on exercise capacity, inspiratory muscles strength, symptoms severity, and health-related quality of life in women diagnosed with fibromyalgia.",[27],{"date":249,"type":32},{"date":297,"type":21},"2026-06-17",{"date":299,"type":21},"2026-11-08",{"name":301,"class":65},"Middle East University",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":66},"100625495","vestibular-innovation-in-pain-2-100625495","NCT07423377","Vestibular Innovation in Pain 2","Vestibular Innovation in Pain: A Randomized Controlled Trial","VIPR","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Age equal to or \\>18 years old\n* Stated interest in and willingness to receive VCS and to complete the online patient reported outcomes before and after the procedure.\n* Owns or has access to a smart phone or computer to complete outcome measures\n* Fluency in English\n* Diagnosis of Fibromyalgia (FM)\n\n  * Diagnosis by American College of Rheumatology 2016 questionnaire\n  * Pain score 4\u002F10 or more and less than 10\u002F10 on the numeric rating scale at the time of inclusion.\n\nExclusion Criteria:\n\n* History of tympanic membrane injury, rupture, or surgery a. Including tympanostomy, or \"ear tubes,\" and\u002For cochlear implant.\n* Right ear infection within the last 3 months, or current right ear pain.\n* Current pregnancy\n* Bipolar Disorder\n* History of seizures (including non-epileptiform seizures)\n* History of syncope within the last 3 months. a. Not including presyncope or in setting of known medical illness (i.e., heatstroke)\n* Inability to lay supine for 15 minutes\n* Receiving disability benefits for fibromyalgia or involved in litigation related to fibromyalgia.\n* Clinically significant medical, psychological, or behavioral conditions that, in the opinion of the investigator, would compromise participation in the study.\n* History of or current Meniere's Disease\n* History of myocardial infarction (MI), stroke or TIA, or coronary artery bypass graft (CABG) in the last 3 months\n* History of hospitalization for severe hypertension\n* History of vestibular schwannoma or meningioma resection.\n* Patients taking opioid therapy (not including tramadol).",{"count":311,"type":21},56,[24],"Fibromyalgia is the most common centralized pain disorder, affecting up to 3% of the population. Current treatments are incompletely effective, often poorly tolerated, and costly: there remains an urgent need for novel, effective, and well-tolerated therapy. Preliminary data suggests that vestibulocortical stimulation (VCS), or irrigating the external ear canal with temperate water, could rapidly improve pain and quality of life in this cohort. The VIPR trial will assess the efficacy of a single session of VCS - a safe \\& cost-effective bedside technique using a plastic syringe and temperate water - relative to sham in treating pain \\& improving quality of life using validated patient-reported outcomes.",[27,109],[316,317],"pain","quality of life","2026-06-05",{"date":275,"type":32},{"date":321,"type":32},"2026-03-19",{"date":323,"type":21},"2027-07-31",{"name":325,"class":65},"Icahn School of Medicine at Mount Sinai",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":333,"sex":17,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":345,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":66},"100501841","supraspinal-processing-of-sensory-aspects-of-pain-100501841","NCT05814497","Supraspinal Processing of Sensory Aspects of Pain","SCP","Inclusion Criteria:\n\n* Patients will need a diagnosis of a chronic pain derived congruent with ICD-11 criteria related to headache (migraine, daily headache), abdominal (FAPD), localized MSK (single limb\u002Fjoint, low back or chest pain), diffuse MSK (widespread MSK pain), or CRPS\n* If on medications, they need to be on stable doses of prescribed pain and\u002For psychiatric medications for 4 weeks before the baseline study visit.\n* Male or female, age 10 -17 (inclusive)\n* English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Weight\u002Fsize incompatible with MRI scanner\n* Orthodontic braces, metallic or electronic implants, or other metal objects in the body which obscure or interfere with the MRI, or pose a risk from heating, movement, or malfunction in the MRI environment\n* Claustrophobia\n* Youth who are pregnant\n* Any comorbid rheumatic disease, diagnosis of epilepsy, other neurological diseases, or medical condition (e.g. diabetes, cancer, IBD)\n* Present psychiatric disease as defined by DSM IV (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, ADHD, or mental retardation) that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study\n* Skin conditions or past skin damage on the arms or legs in or near sites of sensory testing\n* Outside the age range (9 years old or younger; 18 years or older) at the time of consent\n* History of \\> 1 month opioid treatment.",true,"10 Years","17 Years",{"count":337,"type":21},255,[24],"The goal of this basic science study is to learn about the brain mechanisms of chronic pain across different chronic pain syndromes in pediatric patients. The main questions it aims to answer are:\n\n* Are there shared and distinct brain systems engaged by different forms of pediatric chronic pain?\n* What are predictors of recovery from chronic pain?\n* What brain systems are associated with the spread of pain?\n\nFor this study participants will undergo:\n\n* Functional Magnetic Resonance Imaging (fMRI)\n* Quantitative Sensory Testing\n* Psychological Assessments",[341,342,343,344,27],"Migraine in Children","Complex Regional Pain Syndromes","Musculoskeletal Pain","Functional Abdominal Pain Syndrome",[346],"chronic pain","2026-06-04",{"date":318,"type":32},{"date":350,"type":32},"2023-05-01",{"date":352,"type":21},"2027-06-30",{"name":354,"class":65},"Children's Hospital Medical Center, Cincinnati",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":66},"100643267","empowered-relief-for-caregivers-100643267","NCT07636980","Empowered Relief for Caregivers","Empowered Relief for Caregivers (ER-CY): A Co-Designed Brief Intervention to Support Families of Youth With Chronic Pain","ER-CY","Inclusion Criteria:\n\n* Caregiver of a youth with a chronic pain diagnosis (\\>3 months in duration)\n* English speaking\n\nExclusion Criteria:\n\n* Significant psychosocial complexity based on clinical team assessment (e.g., severe depression\u002Fanxiety, unable to tolerate a group setting)",{"count":364,"type":21},80,[24],"This study is testing a new program called Empowered Relief for Caregivers (ER-CY), designed to support caregivers of children and teens who live with chronic pain. ER-CY is a single two-hour class delivered online. It teaches skills for managing the stress of caring for a child in pain and for responding to a child's pain in helpful ways.\n\nUp to 80 caregivers of youth with chronic pain will take part in one ER-CY class and then complete surveys and a short interview over the following three months. The researchers want to learn two things: whether caregivers are willing and able to take part and find the program helpful and satisfying, and whether the program lowers caregiver distress and improves their child's day-to-day functioning. What is learned will help guide future programs and care for youth with chronic pain and their families.",[108,343,27,368,369,370],"Neuropathic Pain","Complex Regional Pain Syndromes (CRPS)","Abdominal Pain (AP)","2026-06-03",{"date":373,"type":32},"2026-06-09",{"date":210,"type":21},{"date":376,"type":21},"2028-09",{"name":378,"class":65},"Stanford University",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":178,"minAge":48,"maxAge":49,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":66},"100638888","effect-of-reflexology-on-pain-and-sleep-disorders-in-females-with-fibromyalgia-100638888","NCT07614945","Effect of Reflexology on Pain and Sleep Disorders in Females With Fibromyalgia","The Effect of Reflexology on Pain and Sleep Disorders in Females With Fibromyalgia: A Randomized Controlled Trial","REFLEX-FM","Inclusion Criteria:\n\n* Egyptian female participants aged 18 to 65 years\n* Diagnosis of fibromyalgia according to American College of Rheumatology (ACR) criteria\n* Moderate pain intensity\n* Poor sleep quality\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Comorbid conditions affecting pain or sleep, including rheumatoid arthritis and related disorders\n* Previous reflexology treatment within the previous 6 months\n* Any medical condition preventing participation in physical therapy or reflexology intervention\n* Refusal or inability to comply with study procedures and follow-up requirements",{"count":51,"type":21},[24],"This randomized controlled trial aims to investigate the effect of foot reflexology on pain and sleep disorders in Egyptian female patients with fibromyalgia. Sixty female participants aged 18 to 65 years diagnosed with fibromyalgia will be randomly assigned into two equal groups. The control group will receive conventional physical therapy, including aerobic exercise, resistance training, and transcutaneous electrical nerve stimulation (TENS), while the experimental group will receive the same treatment in addition to foot reflexology. Interventions will be delivered twice weekly for six weeks. Pain, sleep quality, psychological distress, and functional activity will be evaluated at baseline and after treatment using validated Arabic assessment tools and pressure pain threshold measurements. The study aims to determine whether reflexology provides additional benefits when combined with conventional physical therapy in women with fibromyalgia.",[27],[27,392,393,108,394,395,396,81,397,398,399,400],"Reflexology","Foot Reflexology","Sleep Disorders","Physical Therapy","TENS","Pain Management","Women Health","Complementary Therapy","Randomized Controlled Trial",{"date":347,"type":32},{"date":371,"type":21},{"date":404,"type":21},"2026-10-31",{"name":406,"class":65},"Cairo University",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":66},"100559726","fibromyalgia-sleep-a-to-zzz-study-100559726","NCT06567886","Fibromyalgia Sleep A to ZZZ Study","At Home Morning Bright Light Treatment for Chronic Nociplastic Pain","Inclusion Criteria:\n\n1. Meets 2016 revised diagnostic criteria for fibromyalgia (FM)\n2. Has access to video conferencing (including web cameras and audio) and a private space for the remote study visits.\n\nExclusion Criteria:\n\n1. Significant chronic disease\n2. Severe hearing or memory problems\n3. Pending medical leave applications at workplace\n4. Current pregnancy, breastfeeding, or actively trying to get pregnant\n5. Night work or travel outside the eastern time zone within 1 month of the study\n6. Other research participation\n7. Frequent number of special events during study period (weddings, concerts, exams, etc).",{"count":415,"type":21},390,[24],"This research study is testing whether changes in sleep timing and morning light therapy may have an impact on symptoms related to fibromyalgia.",[27],[420,421],"Sleep timing stabilization","Morning light therapy","2026-06-02",{"date":347,"type":32},{"date":425,"type":32},"2024-09-27",{"date":427,"type":21},"2029-03",{"name":429,"class":65},"University of Michigan",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":178,"minAge":48,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":4},"100633313","pain--reward-neuromodulation-of-cns-circuits-100633313","NCT07525063","Pain & Reward Neuromodulation of CNS Circuits","PRANCIR","Inclusions:\n\n1. Female and ages 18 +\n2. Ability to read\u002Funderstand English and give consent to participate\n3. Physician diagnosis \\& confirmation of primary fibromyalgia syndrome\n4. Verbal agreement to maintain dose of prescribed medication (if any) constant throughout the study, except exclusion medication and except if there is a medical emergency requiring changes in medication\n5. If enrolled in psychotherapy, verbal agreement to maintain (not change or stop) the psychotherapy during the study\n6. Absence of use of opioid medications (during the previous 90 days, and no greater than a 30-day period during lifetime)\n\nExclusions:\n\n1. limited ability to participate fully in behavioral tasks, longitudinal follow-up (e.g., plans to move out-of-state within 3 months)\n2. MRI contraindication (e.g., metal implants, claustrophobia, pregnant or planning to become pregnant)\n3. any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study (e.g., ongoing legal action or disability claim regarding pain, uncontrolled psychiatric disorder, head\u002Fneck injury, use of certain medications)\n4. male \\*\n\nTMS-Specific Exclusions:\n\n1\\. TMS contraindication (e.g., history of seizures, medications contraindicated for risks\u002Fefficacy of TMS procedures)\n\n1. current hypomania,\n2. meets diagnostic criteria for current psychotic disorder, or psychotic features,\n3. meets diagnostic criteria for Bipolar I disorder,\n4. meets diagnostic criteria for current alcohol or substance use disorder (moderate and high severity)\n5. current uncontrolled anorexia or other condition requiring hospitalization,\n6. current serious medical illness, including current severe migraine headaches,\n7. changed psychotropic medications in the prior 2 months, or plans to change medication during the study,\n8. history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator),\n9. conditions associated with increased intracranial pressure, space occupying brain lesion, transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis,\n10. use of investigational drug or devices within 4 weeks of screening,\n11. cochlear implants,\n12. pregnancy\n\n    * Only females will be enrolled in this study because it focuses on patients who have fibromyalgia which is more prevalent (both diagnosed and self-reported) in females.\n\nDue to the contributions of hormones to the conditions under study in this project, female eligibility in this study will be defined as an individual who is female sex at birth and currently female sex",{"count":438,"type":21},30,[24],"This pilot feasibility study aims to evaluate transcranial magnetic stimulation (TMS) targeting the prefrontal cortex in patients with fibromyalgia syndrome (FMS). The study will assess preliminary efficacy and mechanisms of central nervous system changes using neuroimaging, behavioral tasks, sensory testing, and neuroimmune markers. Participants will undergo MRI scans, multi-day TMS sessions, and complete questionnaires. The goal is to generate pilot data for future trials on neuromodulation for chronic pain.",[81,27,442],"Chronic Pain and Fatigue",[27,444,273,445,446,447,448,449,450,81,316],"Transcranial Magnetic Stimulation","fatigue","cognitive issues","fibro fog","brain fog","trouble sleeping","AFSA","2026-06-01",{"date":371,"type":32},{"date":454,"type":21},"2026-07",{"date":456,"type":21},"2027-06",{"name":458,"class":65},"Duke University",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":333,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":66},"100344043","phase-1-assessment-of-neuroinflammation-in-central-inflammatory-disorders-using-f-18dpa-714-100344043","NCT03759522","Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.","Inclusion Criteria:\n\n1. 18 to 65 years of age\n2. Healthy volunteer OR Clinical diagnosis of Multiple Sclerosis (MS) OR Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome\n\nExclusion Criteria:\n\n1. Contraindication to MRI\n2. Pregnancy\n3. Lactation\n4. Individuals who are unable to participate in the imaging portion due to severity of their medical condition\n5. Chronic infectious disease (e.g. HIV, HCV)\n6. Viral or bacterial illness requiring medical attention and\u002For antibiotics within 1 month of study participation\n7. Diagnosis of cancer, including leukemia\n8. Blood or blood clotting disorder\n9. Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary\n10. Positive urine β-hCG test day of procedure or a serum -hCG test within 48 hours prior to the administration of \\[18F\\]DPA-714\n11. Currently enrolled in a clinical trial utilizing experimental therapies",{"count":466,"type":21},120,[468],"PHASE1","The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia\u002Fmacrophages using the PET radiopharmaceutical \\[F-18\\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \\[F-18\\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia\u002Fmacrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with \\[F-18\\]DPA-714-PET\u002FMRI.",[27,471,472,473],"Chronic Fatigue Syndrome","Multiple Sclerosis","Healthy","2026-05-30",{"date":422,"type":32},{"date":477,"type":32},"2019-02-03",{"date":479,"type":21},"2028-04",{"name":481,"class":65},"University of Alabama at Birmingham",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":333,"sex":17,"minAge":48,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":506,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":66},"100600783","hyperthermia-in-patients-with-chronic-primary-pain---effects-on-thermoregulation-somatosensory-system-and-movement-evoked-pain-100600783","NCT07101978","Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain","Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)","HYPPRI-1","Inclusion Criteria:\n\npatients:\n\n* Confirmed diagnosis of widespread pain (ICD-11 MG30.01)\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9,\n* Pain \\>= 3 month and VAS \\>= 4,0\n* Body - infrared-A-Bulb Distance \\\u003C 38cm (overweight participants)\n* Signed declaration of consent\n\nhealthy:\n\n* No chronic illnesses\n* No acute infections\n* No regular medication: To avoid interactions\n* BMI ≤ 40kg\u002Fcm2\n* Mental health: No psychiatric diagnoses or psychotropic medication in your medical history\n\nExclusion Criteria:\n\n* Participation in other clinical studies\n* Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)\n* Acute and \u002F or feverish microbial infections\n* Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases\n* participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha\u002Fbeta-A(nta)gonists due to a disease from the group described above\n* participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders\n* pregnancy or breastfeeding (for women)\n* Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group","70 Years",{"count":51,"type":21},[24],"This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.",[495,496,497,498,499,500,501,27,502,503,504,505,473],"Hyperthermia","Chronic Primary Pain","Widespread Pain","Muscular Disease","Rheumatic Diseases","Musculoskeletal Diseases","Neuromuscular Disease","Circadian Rhythm","Body Temperature Changes","Somatosensory Function","Quantitative Sensory Testing",[507,508,509,510,511,512],"hyperthermia","widespread pain","chronic primary pain","circadian body temperature","quantitative sensory testing","healthy","2026-05-29",{"date":422,"type":32},{"date":516,"type":21},"2026-08-01",{"date":518,"type":21},"2028-12-31",{"name":520,"class":65},"Bern University of Applied Sciences",{"id":522,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":524,"briefSummary":25,"conditions":525,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":530,"locationsCount":531},"100610366",{"count":20,"type":21},[24],[27],"2026-05-28",{"date":451,"type":32},{"date":34,"type":32},{"date":36,"type":21},{"name":38,"class":39},6,{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":333,"sex":17,"minAge":48,"maxAge":490,"enrollmentInfo":539,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":4},"100638600","the-role-of-resilience-for-physical-functioning-of-patients-with-fibromyalgia-syndrome-using-the-6-min-walk-test-100638600","NCT07611539","The Role of Resilience for Physical Functioning of Patients With Fibromyalgia Syndrome Using the 6-Min Walk Test","6MWT","Inclusion Criteria:\n\n* Ages 18-70\n* Fulfills the 1990 and 2011 American College of Rheumatology Criteria for FM\n* Healthy volunteers: No significant pain\n\nExclusion Criteria:\n\n* Uncontrolled diabetes\n* Cancer\n* Uncontrolled coronary syndromes\n* Peripheral neuropathies\n* Unwillingness\u002Finability to discontinue analgesics, hypnotics, anxiolytics, or stimulants",{"count":540,"type":21},100,"Fibromyalgia (FM) is a prevalent chronic pain disorder, characterized by widespread musculoskeletal pain and fatigue that is associated with significant functional limitations. Its mechanisms are only partially understood. The investigators hypothesize that physical functioning (as measured by the 6-Min Walk Test) of FM patients and healthy controls is negatively influenced by resilience and pain sensitivity. The investigators will perform a case control study to test our hypothesis within and between groups.",[27,543,544],"Physical Function","Six-minute Walk Test","2026-05-22",{"date":526,"type":32},{"date":548,"type":21},"2026-04-30",{"date":550,"type":21},"2031-04-30",{"name":552,"class":65},"University of Florida",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":66},"100548023","auricular-neuromodulation-in-veterans-with-fibromyalgia-100548023","NCT06415591","Auricular Neuromodulation in Veterans With Fibromyalgia","Auricular Neuromodulation in Veterans With Fibromyalgia: A Randomized, Sham-Controlled Study","PENFS","Inclusion Criteria:\n\n* Age 18 years or older; for those who participate in the MRI portion, age 20-60 years old (limit specifically set for participants receiving an MRI scan; limit set to minimize brain structural changes due to aging)\n* For those who participate in the MRI portion, right-handedness, to provide consistency in brain structure and function (limit specifically set for participants receiving an MRI scan; limit set to minimize brain structural changes due to aging)\n* For those who participate in the MRI portion, the ability to safely tolerate MRI\n* Diagnosis of fibromyalgia by the American College of Rheumatology 2016 criteria69\n* Pain score of 4 or greater on DVPRS51 in the 3 months prior to enrollment\n* Intact skin in area of PENFS treatment\n\nExclusion Criteria:\n\n* Pregnancy (self-reported)\n* History of seizures or neurologic conditions that alter the brain\n* Claustrophobia, MRI-incompatible implants, or other conditions incompatible with MRI (only for those who participate in MRI)\n* History of uncontrolled psychiatric illness, autoimmune disease that leads to pain, or skin conditions that can increase risk of infection at PENFS site",{"count":562,"type":21},240,[24],"PENFS (percutaneous electrical nerve field stimulation) is an FDA-cleared acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal. PENFS has been previously shown to provide improvements in fibromyalgia, a difficult to treat chronic pain syndrome, which correlate with changes observed using a special kind of MRI called resting state functional connectivity MRI (rs-fcMRI) that evaluates brain activity at rest. The goals of this study are to rigorously test the initial promising results of PENFS in a much larger group of Veterans suffering from fibromyalgia and to identify potential mechanisms of PENFS effects. Further developing non-pharmacologic therapies for pain can help to improve quality of life and function for those suffering from fibromyalgia and decrease reliance on opioids and other drugs that have numerous side effects for individuals suffering from chronic pain.",[27],[142,27,567,568,569,570],"Magnetic Resonance Imaging","Veterans","Percutaneous Electrical Nerve Field Stimulation","Vagus Nerve","2026-05-19",{"date":545,"type":32},{"date":574,"type":32},"2024-11-01",{"date":576,"type":21},"2028-11-01",{"name":578,"class":579},"VA Office of Research and Development","FED",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":588,"maxAge":589,"enrollmentInfo":590,"targetDuration":592,"studyType":105,"phases":4,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":604,"locationsCount":66},"100640924","the-bridge-pain-study-100640924","NCT07602595","The BRIDGE Pain Study","Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic Pain","BRIDGE","Inclusion Criteria:\n\n* Diagnosis of rheumatic\u002Fautoimmune disease\u002Fpain condition or surgery prior to age 18; Current age 14 to 26 years; Participant (and parent\u002Flegal guardian of participants \\\u003C 18 yo) can read and write in English; At least 1 year from diagnosis of pain or rheumatic disease; For individuals with MSK surgical history, at least 1 year after initial surgical intervention; For individuals with rheumatic disease, their disease must be considered inactive\n\nExclusion Criteria:\n\n* They have active disease, or Other major medical comorbidities have developed after surgery following MSK surgical intervention.","14 Years","26 Years",{"count":591,"type":21},600,"4 Weeks","The purpose of the study is to discover at least two distinct Musculoskeletal pain subtypes. These types are caused by different brain-and-immune system signals that affect how the body feels pain, and they are also shaped by a person's biology, psychology, and social environment.\n\nAim 1. We want to sort adolescents and young adults with long lasting muscle and bone pain into two different groups. To do this, we will look at participants' childhood medical histories, past treatments, when their pain started, the sex they were assigned at birth, what their pain feels like now, tests of how their body senses pain, and immune system markers found in their blood. We think we will find at least two different types of chronic pain groups, plus one group of patients who had a higher risk for pain (because of a rheumatic disease or past surgery) but never developed long term pain.\n\nAim 2. We want to find out if certain patterns of inflammation in the body change how nerve cells react to pain.\n\nAim 3: We want to understand how different biological, psychological, and social factors are connected to the chronic pain groups we identified. We think we will find certain mental, behavioral, and social risks-as well as protective factors-that help explain why some people develop long-lasting pain and others do not. We expect these factors to play different roles in each pain group, including the group that does not develop chronic pain.",[595,27,596,597,598,108,343],"Juvenile Idiopathic Arthritis (JIA)","Lupus","Scoliosis","Pectus Excavatum","2026-05-16",{"date":545,"type":32},{"date":60,"type":21},{"date":603,"type":21},"2029-08",{"name":354,"class":65},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":617,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":66},"100638905","effectiveness-of-oral-magnesium-supplementation-in-fibromyalgia-patients-not-responding-to-standard-treatment-100638905","NCT07585045","Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment","Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment: A Randomized Clinical Trial Using Revised Fibromyalgia Impact Questionnaire","Inclusion Criteria:\n\n1. Patients diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria\n2. Age: 18-65 years.\n3. Not responding to conventional treatment (e.g., amitriptyline, duloxetine, pregabalin) for at least 8 weeks\n4. Patients giving informed consent for enrollment in the study.\n\nExclusion Criteria:\n\n* 1- Patients with renal impairment 2- Pregnant or lactating women 3- Already on magnesium or other mineral supplements 4- Known cases of inflammatory arthritis or other chronic pain syndromes",{"count":613,"type":21},86,[24],"Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questionnaire Revised (FIQR).",[27],[27,618,619],"Magnesium supplement","Revised Fibromyalgia Impact Questionnaire","2026-05-08",{"date":622,"type":32},"2026-05-13",{"date":624,"type":32},"2026-04-16",{"date":626,"type":21},"2027-02-26",{"name":628,"class":65},"Shaikh Zayed Hospital, Lahore"]